STUDIES ON KINETICS OF INHIBITION AND BINDING OF XIIIa BY A CROSS-REACTING ANTIFIBRINOGEN ANTIBODY* by Mitkevich, Olga et al.
Coagulation Factor XIIIa Undergoes a Conformational Change
Evoked by Glutamine Substrate
STUDIES ON KINETICS OF INHIBITION AND BINDING OF XIIIa BY A CROSS-REACTING ANTIFIBRINOGEN
ANTIBODY*
(Received for publication, January 28, 1998)
Olga V. Mitkevich‡, John R. Shainoff§, Patricia M. DiBello, Vivien C. Yee, David C. Teller¶,
Gary B. Smejkal, Paul D. Bishopi, Irina S. Kolotushkina‡, Karl Fickenscher**, and
Gennady P. Samokhin‡‡
From the Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, ‡Institute of Experimental
Cardiology, Russian Cardiology Research Center, Moscow 121552, Russia, ¶Department of Biochemistry, University of
Washington, Seattle, Washington 98195, iZymoGenetics Inc., Seattle, Washington 98102, **Behring Diagnostics GmbH,
Marburg, Germany D-35001, and ‡‡Department of Medicine, East Carolina University School of Medicine,
Greenville, North Carolina 27853
Coagulation factor XIIIa, plasma transglutaminase
(endo-g-glutamine:e-lysine transferase EC 2.3.2.13) cata-
lyzes isopeptide bond formation between glutamine and
lysine residues and rapidly cross-links fibrin clots. A
monoclonal antibody (5A2) directed to a fibrinogen Aa-
chain segment 529–539 was previously observed from
analysis of end-stage plasma clots to block fibrin a-chain
cross-linking. This prompted the study of its effect on
nonfibrinogen substrates, with the prospect that 5A2
was inhibiting XIIIa directly. It inhibited XIIIa-cata-
lyzed incorporation of the amine donor substrate dan-
sylcadaverine into the glutamine acceptor dimethylca-
sein in an uncompetitive manner with respect to
dimethylcasein utilization and competitively with re-
spect to dansylcadaverine. Uncompetitive inhibition
was also observed with the synthetic glutamine sub-
strate, LGPGQSKVIG. Theoretically, uncompetitive in-
hibition arises from preferential interaction of the in-
hibitor with the enzyme-substrate complex but is also
found to inhibit g-chain cross-linking. The conjunction
of the uncompetitive and competitive modes of inhibi-
tion indicates in theory that this bireactant system in-
volves an ordered reaction in which docking of the glu-
tamine substrate precedes the amine exchange. The
presence of substrate enhanced binding of 5A2 to XIIIa,
an interaction deemed to occur through a C-terminal
segment of the XIIIa A-chain (643–658, GSDMTVTVQFT-
NPLKE), 55% of which comprises sequences occurring in
the fibrinogen epitope Aa-(529–540) (GSESGIFTNTKE).
Removal of the C-terminal domain from XIIIa abolishes
the inhibitory effect of 5A2 on activity. Crystallographic
studies on recombinant XIIIa place the segment 643–658
in the region of the groove through which glutamine
substrates access the active site and have predicted that
for catalysis, a conformational change may accompany
glutamine-substrate binding. The uncompetitive inhibi-
tion and the substrate-dependent binding of 5A2 pro-
vide evidence for the conformational change.
Factor XIII (fXIII)1 is a member of the class of enzymes
known as transglutaminases, which catalyze displacement of
amide ammonia at the g-position in glutamine residues by
replacing it with another amine, usually an e-amino group from
a suitable lysine residue (1–4). Formation of e-(g-glutamyl)-
lysine isopeptide bonds functions in both intra- and intermo-
lecular cross-linking of proteins. Among the many functions of
fXIII, the best known are 1) the cross-linking of fibrin, which
stabilizes clots against redissolution by fibrinogen (5) and plas-
min (6), 2) the linking of a2-plasmin inhibitor to fibrin for
further protection from plasmin (7, 8), and 3) the cross-linking
of matrix proteins, among them, fibronectin, collagen, and
thrombospondin, which facilitate wound healing (9). Platelet
and placental fXIII are homodimers composed of two identical
A chains, but plasma fXIII is a heterotetramer composed of two
A and two B chains (10). Plasma fXIII is activated by two steps:
1) thrombin cleavage of a 4 kDa fragment from the N terminus
of the A-chains and 2) Ca-dependent dissociation of the two B
chains from the tetramer, yielding functionally active A-chain
dimers (XIIIa) (11, 12). FXIII was discovered in 1948 (13), and
since that time has been extensively studied. Its primary struc-
ture and its three-dimensional structure including its active
site are all known (14–17). But still unknown are the determi-
nants of substrate docking and specificity (18). Many of the
domains are highly conserved and do not yield antibodies to
probe their function. In this study, we describe multiple types
of inhibition of XIIIa produced with a cross-reacting mono-
clonal antibody (5A2) directed to fibrinogen Aa-chains in the
region of residues 529–539. The modes of inhibition change
from uncompetitive to competitive depending on which sub-
strate (amine donor or glutamine acceptor) is examined and
these changes give insight into the order of substrate usage.
Enhanced binding of 5A2 to XIIIa in the presence of substrate
is viewed as evidence that substrate binding induces conforma-
tional changes in XIIIa. These observations support earlier
inferences on the catalytic mechanism gained from crystallo-
graphic studies on recombinant fXIII A-chains (rXIIIA).
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MATERIALS AND METHODS
Proteins and Reagents—Initial studies on inhibitory effects of 5A2
were carried out directly in plasma. Kinetic studies used ZymoGenetics
Inc. (Seattle, WA) (rXIIIA) (19). Synthetic substrates for XIIIa were
used as supplied in Berichrom® XIIIa assay kits except when supple-
mented with the glutamine substrate LGPGQSKVIG from Behring
Werke (Marburg, Germany). Bovine N,N-dimethylated casein, dan-
sylcadaverine, phenylmethylsulfonyl fluoride, trypsin, dithiothreitol,
Aprotinin®, and guinea pig liver tissue transglutaminase were ob-
tained from Sigma. Bovine thrombin was from U. S. Biochemical Corp.
Hirudin was from Pentapharm AG (Basel). Phenylprolylarginine chlo-
romethyl ketone was from Chemica Alta Ltd (Edmonton, Alberta, Can-
ada). Antifibrinogen monoclonal antibodies (mAb) 5A2 and 7F8 were
made as described previously (20, 21), as was the anti-FPA (22). Anti-
angiotensin-converting enzyme mAb 9B9 (23) was generously provided
by Dr. S. M. Danilov (Russian Cardiology Research Center, Moscow).
Rabbit anti-XIIIa antibodies were generated using rXIIIA as antigen
and purified by elution (0.35 M citrate, pH 3.5) from protein A-Sepha-
rose (Amersham Pharmacia Biotech). Except where indicated, all pro-
tein solutions were in Tris-buffered saline containing 0.1 mM EDTA
(TBSE) at pH 7.4.
Human fibrinogen was purified from the donor plasma by sequential
precipitations with ethanol, glycine, and ammonium sulfate/e-amino
caproic acid as described (24). Where indicated, it was immunochemi-
cally freed of fXIII by passing it (36 mg, 3 ml) through a 10-ml column
of affinity-purified rabbit anti-XIIIa antibody (20 mg) that was linked to
beaded 2% glyoxyl-agarose gel (Global Imports, Tampa, FL) essentially
as described (25). The columns were reused after a flush with 5 ml of 4
M guanidine-HCl and re-equilibrated in TBSE after temporarily resus-
pending the gel in 10 ml of TBSE containing enzyme inhibitors (0.2 mM
phenylmethylsulfonyl fluoride, 0.1 mg/ml Aprotinin®, and 0.1 mM phe-
nylprolylarginine chloromethyl ketone).
Effect of 5A2 on Cross-linking of Fibrinogen—These studies simply
involved adding calcium (5 mM) and dithiothreitol (2.5 mM) in the
presence and absence of added 5A2 (4 mg/ml) to the fibrinogen (2
mg/ml) preparation before removing the contaminating XIIIa from the
fibrinogen. The observed cross-linking was verified as due to the pres-
ence of active XIIIa in the fibrinogen preparation, because it occurred
without thrombin activation and in presence of hirudin, it did not
change during a parallel incubation (6 h, 22 °C) with 8 mg/ml rXIIIA
added, and it did not occur at all after passing the fibrinogen through
the anti-fXIII affinity gel.
Cross-linked products were separated by SDS-polyacrylamide gel
electrophoresis of thiol-reduced specimens and identified after Coomas-
sie staining by comparison with previous electropherograms identifying
the polypeptide chain compositions of the products (26).
Activation of rXIIIA—To preactivate the rXIIIA (2 mg/ml), it was
incubated (15 min, 37 °C) with thrombin (0.5 units/ml) at pH 7.4 in the
presence of CaCl2 (2 mM) and a trace amount of fibrinogen (2 mg/ml).
The activation was then terminated, and thrombin was inactivated
with hirudin (10 units/ml). Activation of rXIIIA that was precoated on
microtiter wells was performed with 0.07 units of thrombin with 5 mM
calcium for 30 min at 37 °C, and the thrombin was subsequently inac-
tivated with 0.3 units of hirudin before washing and blocking for en-
zyme-linked immunosorbent assay measurements.
Assays of XIIIa Activities Using Dimethylcasein As the Glutamine
Substrate and Dansylcadaverine As the Amine Substrate—These assays
followed continuous changes in fluorescence arising from the incorpo-
ration of dansylcadaverine into casein by the method of Lorand et al.
(27). The fluorescence was measured in 96-well microplates using a
Perkin-Elmer luminescence spectrometer LS50, with excitation elicited
at lex 5 360 nm and emission followed at lem 5 510 nm. The buffer
consisted of 0.1 M sodium borate containing 10 mM CaCl2 and 5 mM
dithiothreitol at pH 9.0. The concentrations of preactivated XIIIa in
most of the experiments was 0.03 mg/ml. Dimethylcasein concentra-
tions were varied from 0.06 to 0.38 mg/ml in the presence of a saturat-
ing concentration of dansylcadaverine (200 mM), and dansylcadaverine
concentrations were varied 1–5 mM in the presence of a saturating
concentration of dimethylcasein (5 mg/ml). Reaction rates were as-
sessed during initial stages when fluorescence varied linearly with
time.
Measurements of XIIIa Activity Using Berichrom® fXIII Synthetic
Substrates—This assay uses a synthetic decapeptide (LGPGQSKVIG)
as glutamine substrate and glycine ethyl ester as the amine substrate
and measures transglutaminase activity from the rate of ammonia
release from the peptide using an auxiliary enzyme system (28). The
ammonia release is followed colorimetrically from consumption of
NADH as the ammonia is driven into reaction with a-ketoglutarate by
glutamate dehydrogenase, all of these components apart from NADH
being packaged in the “reporting” solution of the Berichrom® fXIII kit.
The assays were carried out according to the recommended procedure of
the supplier except for two modifications made to characterize the
kinetics of 5A2 inhibition in relation to LGPGQSKVIG concentrations.
We substituted rXIIIA/5A2 mixtures for the plasma specified for meas-
uring plasma fXIII in the kit. Secondly, since the reporting solution
contained a saturating level of LGPGQSKVIG, we diluted it in half and
varied the concentration of LGPGQSKVIG by supplementing the di-
luted solution with added peptide. As determined with the peptide
reconstituted to its original level, apparent reaction velocities, both in
the presence and absence of 5A2 reported with the diluted solutions,
were consistently one-half those reported with the undiluted solution
due to the lower concentration of reporting enzyme (glutamate dehy-
drogenase) in the diluted system.
Preparation of C-terminal-truncated 51-kDa Fragment of rXIIIA—
This tryptic derivative of rXIIIA was prepared essentially as described
by Greenberg et al. (29). The digest contained rXIIIA (2 mg/ml), trypsin
(1 mg/ml), and CaCl2 (10 mM) at 37 °C. SDS-polyacrylamide gel elec-
trophoresis showed that full conversion of rXIIIA to the 51-kDa frag-
ment required 2.5 h of incubation under these conditions. The digestion
was terminated by adding Aprotinin® (0.14 mg/ml). The electrophero-
grams showed that none of the 80-kDa parent rXIIIA remained uncon-
verted. A shorter incubation of 1.5 h left 75% converted. The 51-kDa
fragment precipitated out of solution during the incubation, was cen-
trifuged, and resuspended in TBSE, and the suspension was divided
into 0.1-ml aliquots, which were stored frozen. Just before assay, the
suspension was thawed, and admixed with an equal volume of 6 M urea
(3 M final) to dissolve the protein immediately before measuring its
activity.
Enzyme-linked Immunosorbent Assay for Binding—Nunc immuno
plates (Vanguard Intl., Neptune, NJ) were coated with rXIIIA in TBS
(10 mg/ml, 100 ml/well, 18 h, 4 °C), washed with TBS, and blocked with
3% bovine serum albumin in TBS containing 0.1% Tween-20 (TBSTw).
Primary antibodies, either 5A2 or control anti-FPA mAbs (100 mg/ml,
100 ml/well), were added in 0.1% bovine serum albumin in TBSTw
supplemented with either Behrichrom substrate or blank (10 ml/well).
After 18 h of equilibration at 4 °C followed by a TBSTw wash, the
retained 1° antibody was fixed in place with cold 0.25% glutaraldehyde
in phosphate-buffered saline (100 ml/well, 4 °C, 10 min), and the plates
were washed (TBSTw) and quenched 0.1% bovine serum albumin in
TBSTw (200 ml/well, 37 °C, 10 min). After further washing, secondary
reporter antibody (horseradish peroxidase-goat-anti-mouse Ig at 1:1000
dilution, 100 ml/well) was added, and the excess was washed away after
2 h at 23 °C. Retained 2° antibody was assessed from peroxidase activ-
ity toward orthophenylenediamine.
RESULTS
Inhibitory Effects of mAb 5A2 on Fibrinogen a and g-Chain
Cross-linking—In the course of studies on the effect of 5A2 on
the cross-linking of fibrinogen we observed (Fig. 1) that gg-
dimer formation was inhibited to a degree comparable to the
subsequent (26) incorporation of fibrinogen a-chains2into hy-
brid agg-trimers. The inhibition of g-chain cross-linking was
not detected in our preceding study, which characterized only
the effect of 5A2 on end-stage plasma clots (20). The inhibition
of g-chain cross-linking together with searches indicating that
there was no homology between the 5A2 epitope on fibrinogen
(20) and the amino acid sequences in the fibrinogen g-chains,
prompted us to investigate whether the inhibitory effect of 5A2
was arising from a direct interaction with XIIIa. We then
proceeded to examine the effects of 5A2 on substrates other
than fibrinogen.
Kinetics of Dansylcadaverine Incorporation into Dimethylca-
sein—This reaction was inhibited by 5A2 in a concentration-de-
2 Fibrinogen a-chains (64 kDa) differ from fibrin a-chains by contain-
ing the N-terminal fibrinopeptide A (1.5 kDa) that blocks the fibrin
aggregation site located just penultimate to the fibrinopeptide. The
fibrinogen a-chains are normally designated as Aa-chains except when
qualified as fibrinogen rather fibrin chains. We defer the Aa convention
here to simplify the multimeric structure of the cross-linked chains as
agg trimers rather than Aagg trimers.
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pendent manner and was investigated further in relation to the
utilization of the dimethylcasein (Fig. 2) and the dansylcadaverine
(Fig. 3) at varying concentrations. When dimethylcasein con-
centrations were varied, we obtained parallel, nonintersecting
Lineweaver-Burk plots of 1/y versus 1/[dimethlycasein] at 5A2
concentrations ranging to 0.6 mg/ml (Fig. 2). A replot of the 1/y
intercepts versus the 5A2 concentrations was linear, with a
negative intercept at 5A2 concentrations corresponding to a Ki
of 0.8 mM (Fig. 2, inset). The parallel Lineweaver-Burk plots
and linear replot conformed with a pattern of inhibition termed
“uncompetitive,” where the inhibitor is directed principally to-
ward the enzyme-substrate complex (30), the glutamine sub-
strate in this instance. These effects were specifically caused by
5A2 because no inhibition was observed with 7F8 and were also
specifically directed to XIIIa because no inhibitory effects of
5A2 were observed toward transamination of these substrates
by tissue transglutaminase (negative results not shown).
The Lineweaver-Burk plots of 1/y versus 1/[dansylcadaver-
ine], on the other hand, yielded slopes that varied with the 5A2
concentrations (Fig. 3) and conformed with a competitive mode
of inhibition. A linear replot of the slopes versus 5A2 concen-
trations intercepted the negative 5A2 axis at Ki 5 0.4 mM
(Fig. 3, inset).
Transamination of Berichrom® Decapeptide LGPGQSKVIG
with Glycine Ethyl Ester—As illustrated (Fig. 4), 5A2 exhibited
a concentration-dependent inhibition of XIIIa-catalyzed re-
lease of ammonia from the decapeptide in a pattern consistent
with the uncompetitive mode of inhibition observed with the
other nonfibrinogen-related glutamine substrate, dimethylca-
sein. The 1/y intercepts (corresponding to values for 1/Vmax) at
1/S 5 0 on the Lineweaver-Burk plots varied linearly with 5A2
concentrations (Fig. 4, inset). Extrapolating this replot to the
base-line 1/Vmax 5 0 yielded an estimate of 0.9 mM for the value
of Ki, which could be off by a factor of two (95% confidence
interval) because of the length of the extrapolation.
Homology Searches—The inhibitory effects of 5A2 on utili-
zation of nonfibrinogen substrates and the absence of effect on
tissue transglutaminase suggested that 5A2 was interacting
with a segment of XIIIa with a sequence similar to that of the
fibrinogen epitope. The fibrinogen epitope was identified from
CNBr and tryptic fragments to be located in the region of Aa
529–539, the only fragment from the combined digests that
substantially inhibited (18%) binding of 5A2 to fibrinogen Aa-
chains (20). Searches for similarities between the sequence of
this peptide and the amino acid sequences (16, 31) in XIIIA
were made using both the PROPHET (Bolt Beranek and New-
man, Inc., Cambridge MA) and the BLAST network service
(NCBI). Both searches found a segment near the C terminus of
FIG. 1. Electropherograms illustrating the inhibitory effect of
5A2 on both g- and a-chain cross-linking of fibrinogen by XIIIa.
The first lane (at left) shows the noncross-linked a, b, and g chains in
the parent fibrinogen stored in 0.1 mM EDTA. Cross-linking initiated by
adding calcium and dithiothreitol in the absence of 5A2 (center lane)
caused a nearly complete incorporation of g-chains into characteristic
gg-dimers and subsequent mixed agg oligomers with accompanying
substantial disappearance of noncross-linked a-chains. In the presence
of 5A2 (right lane), the cross-linking of both g- and a-chains was appre-
ciably arrested, as evidenced by the diminished disappearance of non-
cross-linked chains and reductions in the levels of both gg-dimers and
agg-trimers, the percentage change in g- and a-chains products being of
comparable magnitudes. The restoration of noncross-linked g-chains
appears greater than would be expected from the reduced levels of
cross-linked products because 5A2 heavy chains co-migrated in that
band. The light chains from added 5A2 appear at the bottom of the lane.
FIG. 2. Lineweaver-Burk plots characterizing 5A2 as an un-
competitive type of inhibitor of the utilization of glutamine
substrate (dimethylcasein) by rXIIIA. Reaction velocities (y) were
determined from initial rates of increase in fluorescence arising (27)
from incorporation of the dansylcadaverine at fixed concentration into
dimethylcasein at varying concentrations in the presence and absence
of 5A2. The presence of 5A2 diminished reaction velocities (indicated by
the upward shifts in the intercepts on the 1/y axis where 1/y 5 1/Vmaxi,)
but did not alter the slopes, a pattern typical of uncompetitive inhibi-
tion. The inset shows the linear relationship between the 1/y-axis inter-
cepts versus the 5A2 concentrations, which extrapolate to 20.8 mM for
the value of 2Ki.
FIG. 3. Lineweaver-Burk plots characterizing 5A2 as a compet-
itive type of inhibitor of the utilization of amine substrate (dan-
sylcadaverine) by rXIIIA. Reaction velocities (y) were determined as
for Fig. 3, but the concentration of dimethylcasein was fixed at a high
level, and concentrations of dansylcadaverine were varied in the pres-
ence and absence of 5A2. Here, the presence of 5A2 shifted the slopes
rather than the 1/y axis intercepts, a pattern typical of competitive
inhibition. The inset shows the linear relationship between the slopes
versus the 5A2 concentrations, which extrapolate to 20.4 mM for the
value of 2Ki.
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the Aa-chain 643–658 of XIIIA that consists in part (55%) of
sequences occurring in the region of the fibrinogen Aa-chain
epitope, and no other regions were found (.3% homology) in
either XIIIA, fibrinogen, or casein. XIIIA: 643GSDMTVTVQFT-
NPLKE; Fgn Aa: 529GS—GSGIFTN-TKE540.
No Effect on an Enzymically Truncated XIIIA—To test the
importance of the C-terminal domain for the inhibitory effects
of 5A2, we examined its effect on cross-linking of a tryptic
fragment of 5A2 lacking the putative cross-reacting domain.
Greenberg et al. (29) observed that a tryptic fragment of XIIIA
comprising residues Gly38-Lys513 retained 20% of its initial
activity. On trypsinizing rXIIIA we obtained a pure 51-kDa
fragment that precipitated during the digestion. The fragment
exhibited transglutaminase activity in the Berichrom® fXIII
assay when it was admixed (0.015 mg/ml) with the substrates
immediately after dissolving it in 3 M urea. Unlike intact XIIIa,
activity of the fragment was unaffected by 5A2 (Fig. 5). This
result supported the hypothesis that 5A2 was inhibiting intact
XIIIa by interacting with the segment in the XIIIa C-terminal
domain, residues 643–658 with sequence similar to the 5A2
epitope.
Binding of 5A2 with rXIIIA—Attempts to detect binding of
5A2 to plated rXIIIA by enzyme-linked immunosorbent assay
methods failed until we resorted to fixing the initially bound
5A2 with glutaraldehyde to prevent dissociative losses during
FIG. 4. Effect of 5A2 on transglutaminase activity of rXIIIA
toward Berichrom® fXIII synthetic substrates (recorded from
changes in absorbance (l 5 340 nm) due to the color reaction of
ammonia released from LGPGQSKVIG by glycine ethyl ester in
the presence of varying concentrations of 5A2). Reaction veloci-
ties (y) were calculated from linear least square slopes of the plots. Inset,
replot of the reciprocal slopes (1/y) versus the concentrations of inhibitor
(5A2). The intercept at 20.9 mM 5A2 represents the value of 2Ki.
FIG. 5. Comparison of effects of 5A2 on activities of rXIIIA and
the trypsin-truncated rXIIIA using the Berichrom® fXIII assay
kit.
FIG. 6. Effect of adding (1) or omitting (2) the Berichrom®
substrate on the binding of 5A2 and control (anti-FPA) mAbs to
rXIIIA plated either 1) without activation (XIIIA), 2) preacti-
vated with thrombin (XIIIa), or 3) without pre-activation but
activated with thrombin after plating (XIIIA*). ELISA, enzyme-
linked immunosorbent assay.
FIG. 7. Model of XIIIA dimer adapted from Yee et al. (17) show-
ing the location of the cross-reacting segment 643–658 situated
in barrel 2 through which glutamine substrates are deemed to
access the catalytic domain. The illustration was generated using
computer programs MolScript (36) and Raster3D (37).
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exposure (30 min) to secondary, reporter antibody. This ap-
proach detected binding of 5A2 to the rXIIIA zymogen substan-
tially above that of a control mAb, anti-FPA (Fig. 6). Activating
the rXIIIA with thrombin promoted binding of both the 5A2
and anti-FPA mAbs (5A2 more so), whether the activation was
performed before plating the rXIIIA (columns labeled XIIIa) or
after plating (columns labeled XIIIA*). We suspect that the
enhanced binding of the anti-FPA was due to an effect of
thrombin, because plating thrombin caused some retention of
the anti-FPA not observed with 5A2. Unlike the binding of
anti-FPA, the 5A2 binding became substantially enhanced fur-
ther when the synthetic substrate from the Berichrom® fXIII
kit was added to the medium during incubation. The added
substrate also caused a slight increase in binding to the zymo-
gen, which could conceivably be due to the normal development
of low levels of activity by zymogen without thrombin treat-
ment. Essentially the same enhancing effects of added sub-
strate were reproducibly obtained in repeated experiments.
The enhanced binding of 5A2 after activation with thrombin
and the further enhancement after adding substrate were
viewed as indications that substrate binding was inducing a
conformational change leading to greater exposure of the
epitope for 5A2 binding.
DISCUSSION
The C-terminal domain of XIIIA had been shown by Green-
berg et al. (29) to have some influence on the transglutaminase
activity of the enzyme, as judged by the substantial (80%) loss
of activity after removing the domain with trypsin. Attempts to
probe its function immunochemically have proven difficult,
because it is poorly immunogenic (29). As described here, we
serendipitously found that an antibody (5A2) directed to a
C-terminal domain of the fibrinogen Aa-chain (529–539) inhib-
its XIIIa in a manner dependent on the C-terminal domain of
the enzyme. This inhibition is deemed to involve a cross-reac-
tivity with residues 643–658 in the XIIIA chain, which share
homology with the fibrinogen epitope, and further appears to
be partially dependent on interaction with XIIIa complexed
with substrate. The modes of inhibition have important impli-
cations for the structure and activity of XIIIa.
The crystallographic structure of XIIIA was recently eluci-
dated (17, 32, 33). As illustrated (Fig. 7), the cross-reacting
segment 643–658 forms a strand in the outer b sheet of the C
terminus of the barrel 2 domain of XIIIA. The lysine 657
residue is located at the gap between the barrel 1 and barrel 2
domains, which has been identified as one of two possible loci
through which glutamine substrates gain access to the cata-
lytic site of the enzyme (32). The inhibition of utilization of
glutamine substrates (both the dimethylcasein and the syn-
thetic peptide LGPGQSKVIG) was uncompetitive, an indica-
tion (30) that the principal mode of that inhibition was directed
to the enzyme-glutamine complex. Any other mode of enzyme-
inhibitor interaction is incidental. In essence, the glutamine
binding acts as an activator of the catalytic conformational
change that enables utilization of the amine substrate. Utili-
zation of the amine substrate was inhibited competitively,
probably not because 5A2 acts as an analog of the amine
substrate, but, more likely, because the amine substrate cannot
bind to the ternary glutamine donorzXIIIaz5A2 complex. The
independent observation of increased 5A2 binding to XIIIa in
the presence of glutamine substrate is consistent with that
explanation. Thus, these two modes of inhibition indicate that
the transamination reaction is an ordered event dependent on
docking of the glutamine substrate to trigger reaction with
subsequent binding of the amine substrate.
Binding of 5A2 to XIIIa was enhanced by co-incubation with
the Berichrome® fXIII substrate system, an indication that
substrate binding enhances exposure of the 5A2 epitope on
XIIIa. It had been predicted that a conformational change
accompanying the glutamine binding functions in the catalytic
activity of the enzyme (32). Crystal structures of rXIIIA both
before and after activation with either thrombin or high con-
centrations of calcium (34, 35) led to the inference that the
conformational change that must accompany catalysis arises
from the docking of the glutamine substrate. Our findings
provide evidence for a substrate-induced conformational
change and primacy of glutamine binding in the catalytic
reaction.
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